LUF6283 is a potent and orally activeHCA(2)partial agonist, with aK_iof 0.55 μM. LUF6283 can achieve the beneficial lipid lowering effect of niacin without producing the unwanted cutaneous flushing side effect^[1].

EC₅₀: 0.32 ± 0.06 μM (pERK1/2)^[1]

LUF6283 (C57BL/6 mice, 400 mg/kg, Oral gavage, once a day for 4 weeks) has no effect on adipose tissue ATGL/HSL expression, and significantly reduces the expression of apolipoprotein B (APOB)^[1].

168.19

C₈H₁₂N₂O₂

92933-48-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.